MedPage Today Most Work Stops on Major Alzheimer's Drug MedPage Today By John Gever, Senior Editor, MedPage Today In the wake of another negative trial with the anti-amyloid biologic drug bapineuzumab, Pfizer and Janssen said they were halting development of the product for mild to moderate Alzheimer's disease. Pfizer, Johnson & Johnson To Stop Trials of Alzheimer's Drug Wall Street Journal The Bapi Bust: Pfizer & J&J Shut Down Alzheimer's Phase 3 Program Forbes News Summary: Pfizer, J&J Alzheimer's drug fails The Associated Press all 221 news articles »
Visit site:
Most Work Stops on Major Alzheimer's Drug - MedPage
Brak komentarzy:
Prześlij komentarz